The deubiquitinating enzyme ATXN3 promotes the progression of anaplastic thyroid carcinoma by stabilizing EIF5A2

• DOI: 10.1016/j.mce.2021.111440
• Publication Date: 2021-08-21T05:55:13Z
• Authors: Shimin Zhuang; Jing Xie; Jing Zhen; Liangyun Guo; Zhengdong Hong; Feihong Li; Debin Xu
• Keywords: 0301 basic medicine; Protein Stability; Ubiquitination; Mice, Nude; RNA-Binding Proteins; Eukaryotic Translation Initiation Factor 5A; Thyroid Carcinoma, Anaplastic; Up-Regulation; 3. Good health; Gene Expression Regulation, Neoplastic; Repressor Proteins; 03 medical and health sciences; Peptide Initiation Factors; Cell Line, Tumor; Disease Progression; Animals; Humans; Neoplasm Metastasis; Ataxin-3; Cell Proliferation

Ataxin-3 (ATXN3) is a ubiquitous deubiquitinating enzyme that plays an essential role in the carcinogenesis of numerous tumors and stabilizes the expression of substrates by deubiquitination. However, the functional role of ATXN3 in anaplastic thyroid carcinoma (ATC) remains unknown. In this research, we report that ATXN3 was overexpressed in ATC compared to that in paracancerous samples. Moreover, various gain/loss functional assays were performed to indicate that ATXN3 overexpression enhanced ATC cell proliferation and metastasis. We also found that ATXN3 and eukaryotic translation initiation factor 5A2 (EIF5A2) protein levels in ATC tissues are positively correlated, and ATXN3 promotes the proliferation and metastasis of ATC cells through EIF5A2. Mechanistically, ATXN3 promotes EIF5A2 expression by directly binding to EIF5A2 to reduce its ubiquitination and degradation. Therefore, for the first time, we clarified the role of ATXN3 in the carcinogenesis of ATC cells, which provides novel insights into potential therapeutic targets for ATC progression.